MEDICALLY REVIEWED

FDA Approves Omisirge Cell Therapy to Reduce Infection Risk in Patients with Hematologic Malignancies

Chemotherapy
Omisirge is used in adults and children aged 12+ for cord blood transplant after myeloablative conditioning in hematologic malignancies.

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: